We’re excited to continue our 2026 PEAKS® Webinar Series on March 4th, with the next session titled “DDA, DIA, or PRM? 3-in-1 Proteomic Solutions in a High-Throughput Era". In this lecture we will demonstrate PEAKS® Studio's key strength—a 3-in-1 comprehensive solution, which switches seamlessly between discovery (DDA/DIA) and validation (PRM) proteomic workflows.
Led by our experienced Software System Manager, Qing Zhang, MSc., this 45-minute lecture will introduce PEAKS® “one-stop” solution for different data acquisition methodologies (discovery, targeted, and hybrid) and highlight applications in precision medicine (from discovery to validation) and immunopeptidomics (de novo-based non-canonical epitope discovery).
With the ongoing fast-paced development of LC-MS/MS instrumentation and strategies such as ZT Scan or narrow-window DIA, nowadays proteomics research has stepped into a high throughput era with innovative and specialized applications and thus data acquisitions. This requires an effective and elaborate data processing pipeline, which can handle a wide range of data types with identification depth and confidence as well as high quantification accuracy within one unified software platform.
Whether you are looking to maximize your biomarker, drug, or pathogen discovery depth or you are immersed in clinical diagnostics and biomarker validation, PEAKS® Studio 13.1 empowers your research with integrated solutions in a single, high-performance software engine.
Stick around for an interactive Q&A at the end, where we’ll address your workflow‑specific questions.
What You'll Learn
- Unified Workflows: Process DDA, DIA, and PRM data seamlessly within a single interface to reduce the learning curve.
- Deep Identification: Leveraging PEAKS’ signature de novo sequencing to enable specialized algorithms for a wide range of applications.
- Quantification Accuracy: Achieving high sensitivity and reproducibility essential in clinical diagnostics and industrial quality control.
Who Should Attend?
- Proteomics researchers and core facilities working with high‑throughput discovery, targeted, or hybrid workflows.
- Translational and precision medicine teams moving from biomarker discovery to confident validation.
- Immunopeptidomics and neoantigen researchers interested in leveraging de novo–based workflows
Event Details
📅 Date: March 4th, 2026
🕰️ Times: 10:00 a.m. & 4:00 p.m. EST (two sessions to accommodate global audiences)
ℹ️ Format: Virtual (Zoom links sent upon registration confirmation)
Ready to elevate your proteomics capabilities? Secure your spot today!